Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label garadacimab prophylaxis study in hereditary angioedema
NL-OMON54235Phase 3Recruiting
- Sponsor
- CSL Behring
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoint: Long-term safety of subcutaneous garadacimab. Started Dec 2021; status: recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON54235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54235.